在使用HeartMate 3左心室辅助装置的门诊患者中,有或没有低分子肝素桥接的血液相容性相关不良事件

IF 2.2 3区 医学 Q3 ENGINEERING, BIOMEDICAL
Julia R James, Madeline Fuller, Madison Hanford Hunt, Elizabeth Powell, Gary Lu, Quefeng Li, Arwa Omary, Ian B Hollis
{"title":"在使用HeartMate 3左心室辅助装置的门诊患者中,有或没有低分子肝素桥接的血液相容性相关不良事件","authors":"Julia R James, Madeline Fuller, Madison Hanford Hunt, Elizabeth Powell, Gary Lu, Quefeng Li, Arwa Omary, Ian B Hollis","doi":"10.1111/aor.14986","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Prior studies of anticoagulation bridging during periods of low International Normalized Ratio (INR) in outpatients with a durable, continuous flow left ventricular assist device (CF-LVAD) have shown a variable impact on thrombotic and bleeding events. These studies include predominantly older devices such as the HeartMate 2 (HM2) and HeartWare HVAD, which are known to experience more overall thrombotic events than the HeartMate 3 (HM3) device. The majority of these patients also received concomitant aspirin.</p><p><strong>Methods: </strong>The primary objective of this study was to compare hemocompatibility-related adverse events (HRAEs) occurring while bridging subtherapeutic (≤ 1.7) INRs with therapeutic low-molecular weight heparin (LMWH) versus not bridging in outpatients with an HM3 CF-LVAD, many of whom were not receiving concomitant aspirin.</p><p><strong>Results: </strong>Of the 79 patients eligible for inclusion in this study, 64 were not bridged and 15 were bridged at least once during the study period. In the non-bridged group, there were a total of 12 HRAEs of 997 bridging opportunities (BOs) (1.20%) versus 0 of 39 BOs in the bridged group. Of the 12 HRAEs in the non-bridged group, 10 were bleeding events; the 2 thrombotic events were minor venous thromboembolisms.</p><p><strong>Conclusion: </strong>Omission of LMWH bridging in HM3 CF-LVAD patients with a subtherapeutic INR and low rates of background aspirin use did not result in a statistically significant or clinically relevant increase in the rate of HRAEs.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hemocompatibility-Related Adverse Events Associated With or Without Low Molecular Weight Heparin Bridging in Outpatients With a HeartMate 3 Left Ventricular Assist Device.\",\"authors\":\"Julia R James, Madeline Fuller, Madison Hanford Hunt, Elizabeth Powell, Gary Lu, Quefeng Li, Arwa Omary, Ian B Hollis\",\"doi\":\"10.1111/aor.14986\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Prior studies of anticoagulation bridging during periods of low International Normalized Ratio (INR) in outpatients with a durable, continuous flow left ventricular assist device (CF-LVAD) have shown a variable impact on thrombotic and bleeding events. These studies include predominantly older devices such as the HeartMate 2 (HM2) and HeartWare HVAD, which are known to experience more overall thrombotic events than the HeartMate 3 (HM3) device. The majority of these patients also received concomitant aspirin.</p><p><strong>Methods: </strong>The primary objective of this study was to compare hemocompatibility-related adverse events (HRAEs) occurring while bridging subtherapeutic (≤ 1.7) INRs with therapeutic low-molecular weight heparin (LMWH) versus not bridging in outpatients with an HM3 CF-LVAD, many of whom were not receiving concomitant aspirin.</p><p><strong>Results: </strong>Of the 79 patients eligible for inclusion in this study, 64 were not bridged and 15 were bridged at least once during the study period. In the non-bridged group, there were a total of 12 HRAEs of 997 bridging opportunities (BOs) (1.20%) versus 0 of 39 BOs in the bridged group. Of the 12 HRAEs in the non-bridged group, 10 were bleeding events; the 2 thrombotic events were minor venous thromboembolisms.</p><p><strong>Conclusion: </strong>Omission of LMWH bridging in HM3 CF-LVAD patients with a subtherapeutic INR and low rates of background aspirin use did not result in a statistically significant or clinically relevant increase in the rate of HRAEs.</p>\",\"PeriodicalId\":8450,\"journal\":{\"name\":\"Artificial organs\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-03-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Artificial organs\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.1111/aor.14986\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENGINEERING, BIOMEDICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Artificial organs","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1111/aor.14986","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:先前的研究表明,在使用持久、连续血流左心室辅助装置(CF-LVAD)的门诊患者的低国际标准化比率(INR)期间抗凝桥对血栓和出血事件有不同的影响。这些研究主要包括较老的设备,如HeartMate 2 (HM2)和HeartWare HVAD,已知它们比HeartMate 3 (HM3)设备经历更多的整体血栓事件。这些患者中的大多数还同时服用阿司匹林。方法:本研究的主要目的是比较HM3 CF-LVAD门诊患者在亚治疗性(≤1.7)INRs与治疗性低分子肝素(LMWH)桥接与未桥接时发生的血液相容性相关不良事件(HRAEs),其中许多患者未同时服用阿司匹林。结果:本研究纳入的79例患者中,64例未进行桥接,15例在研究期间至少进行了一次桥接。在非桥接组中,共有997个桥接机会(BOs)的12个hrae(1.20%),而桥接组中有39个BOs的0个。非桥接组12例hrae中,10例为出血事件;2例血栓事件均为轻微静脉血栓栓塞。结论:在低治疗INR和低背景阿司匹林使用率的HM3 CF-LVAD患者中,忽略低分子肝素桥接不会导致HRAEs发生率的统计学显著或临床相关的增加。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Hemocompatibility-Related Adverse Events Associated With or Without Low Molecular Weight Heparin Bridging in Outpatients With a HeartMate 3 Left Ventricular Assist Device.

Background: Prior studies of anticoagulation bridging during periods of low International Normalized Ratio (INR) in outpatients with a durable, continuous flow left ventricular assist device (CF-LVAD) have shown a variable impact on thrombotic and bleeding events. These studies include predominantly older devices such as the HeartMate 2 (HM2) and HeartWare HVAD, which are known to experience more overall thrombotic events than the HeartMate 3 (HM3) device. The majority of these patients also received concomitant aspirin.

Methods: The primary objective of this study was to compare hemocompatibility-related adverse events (HRAEs) occurring while bridging subtherapeutic (≤ 1.7) INRs with therapeutic low-molecular weight heparin (LMWH) versus not bridging in outpatients with an HM3 CF-LVAD, many of whom were not receiving concomitant aspirin.

Results: Of the 79 patients eligible for inclusion in this study, 64 were not bridged and 15 were bridged at least once during the study period. In the non-bridged group, there were a total of 12 HRAEs of 997 bridging opportunities (BOs) (1.20%) versus 0 of 39 BOs in the bridged group. Of the 12 HRAEs in the non-bridged group, 10 were bleeding events; the 2 thrombotic events were minor venous thromboembolisms.

Conclusion: Omission of LMWH bridging in HM3 CF-LVAD patients with a subtherapeutic INR and low rates of background aspirin use did not result in a statistically significant or clinically relevant increase in the rate of HRAEs.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Artificial organs
Artificial organs 工程技术-工程:生物医学
CiteScore
4.30
自引率
12.50%
发文量
303
审稿时长
4-8 weeks
期刊介绍: Artificial Organs is the official peer reviewed journal of The International Federation for Artificial Organs (Members of the Federation are: The American Society for Artificial Internal Organs, The European Society for Artificial Organs, and The Japanese Society for Artificial Organs), The International Faculty for Artificial Organs, the International Society for Rotary Blood Pumps, The International Society for Pediatric Mechanical Cardiopulmonary Support, and the Vienna International Workshop on Functional Electrical Stimulation. Artificial Organs publishes original research articles dealing with developments in artificial organs applications and treatment modalities and their clinical applications worldwide. Membership in the Societies listed above is not a prerequisite for publication. Articles are published without charge to the author except for color figures and excess page charges as noted.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信